Canaccord Genuity Maintains Buy on CareDx, Raises Price Target to $80
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Kyle Mikson maintains CareDx (NASDAQ:CDNA) with a Buy and raises the price target from $65 to $80.
Canaccord Genuity analyst Kyle Mikson maintains CareDx (NASDAQ:CDNA) with a Buy and raises the price target from $65 to $80.